Key result
Adipose tissue dysfunction and insulin resistance are central to the pathogenesis of non-alcoholic fatty liver disease, which is considered the hepatic manifestation of the metabolic syndrome.
This review summarizes the interrelationship between non-alcoholic fatty liver disease, adipose tissue, insulin resistance, and metabolic syndrome, highlighting current diagnostic and therapeutic approaches.
Supports metabolic screening in NAFLD; leaves open targeted adipose therapies pending interventional trials.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally, and it is expected to rise even further as a result of the increase in obesity and related risk factors. This short review summarises current evidence on the role of adipose tissue and insulin resistance in NAFLD and the interrelationship between NAFLD and the metabolic syndrome (MetS), considering central adiposity is a major feature of both the MetS and NAFLD, and that NAFLD has been previously described as the hepatic manifestation of the MetS. In addition, genetic studies of NAFLD with relation to adiposity and insulin resistance are reviewed, and up-to-date diagnostic and therapeutic tools are also discussed.
No takes yet. Share an insight, caveat, or question.
Κouis et al. (2014) conducted a review in Non-alcoholic fatty liver disease (NAFLD). Adipose tissue dysfunction and insulin resistance are central to the pathogenesis of non-alcoholic fatty liver disease, which is considered the hepatic manifestation of the metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: